Details of Disease

General Information of Disease (ID: DIS3FXDI)

Disease Name	Mucositis
Synonyms	mucosa inflammation; inflammation of mucosa; mucositis
Disease Class	CA00: Nasopharyngitis
Definition	Inflammation of the mucous membranes.
Disease Hierarchy	DIS184KT: Skin inflammation DISWD40R: Disease DIS3FXDI: Mucositis
ICD Code	ICD-11 ICD-11: CA00 ICD-10 ICD-10: J00 ICD-9 ICD-9: 528 Expand ICD-9 528
Disease Identifiers	MONDO ID MONDO_0020579 MESH ID D052016 UMLS CUI C0333355 MedGen ID 87165 SNOMED CT ID 87749000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adalimumab	DMQMV1B	Approved	Antibody	[1]
Amifostine	DM5FL14	Approved	Small molecular drug	[2]
L-alanyl-l-glutamine	DMANBR7	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SNX-1012	DMBYU3S	Discontinued in Phase 1	NA	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IMX-942	DMV5KSA	Preclinical	NA	[4]
Mteron-F1	DMCZW4Q	Preclinical	NA	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DW-800	DM98ITF	Investigative	NA	[6]
EX-201	DMY3J6G	Investigative	NA	[6]
PRO-300	DM1FS2H	Investigative	NA	[6]
TK-112690	DMKV52P	Investigative	NA	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IL1RN	TT6GSR3	Limited	Therapeutic	[8]
CSF2	TTNYZG2	Strong	Biomarker	[9]
RSPO1	TTI9HL4	Strong	Biomarker	[10]
TGFA	TTTLQFR	Strong	Therapeutic	[11]
ELANE	TTPLTSQ	Definitive	Biomarker	[12]
MKI67	TTB4UNG	Definitive	Biomarker	[13]
PCNA	TTLG1PD	Definitive	Biomarker	[14]
ULK1	TT4D7MJ	Definitive	Therapeutic	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DTT(s)

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
TFF3	OTJJDRTU	Strong	Therapeutic	[16]
MUC2	OT3X4QVX	Definitive	Biomarker	[17]
MUC4	OTLT11V1	Definitive	Biomarker	[17]
------------------------------------------------------------------------------------

References

1	Identification of potential molecular mechanisms and candidate drugs for radiotherapy- and chemotherapy-induced mucositis. Support Care Cancer. 2023 Mar 20;31(4):223.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016267)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018500)
5	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
6	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7	CN patent application no. 102014919, Methotrexate adjuvants to reduce toxicity and methods for using the same.
8	Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice.Cancer Chemother Pharmacol. 2011 Jul;68(1):87-96. doi: 10.1007/s00280-010-1451-5. Epub 2010 Sep 16.
9	Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.J Clin Oncol. 1994 Mar;12(3):560-8. doi: 10.1200/JCO.1994.12.3.560.
10	Inducing intestinal growth.N Engl J Med. 2005 Nov 24;353(21):2297-9. doi: 10.1056/NEJMcibr053367.
11	Effect of transforming growth factor-alpha on enterocyte apoptosis is correlated with EGF receptor expression along the villus-crypt axis during methotrexate-induced intestinal mucositis in a rat.Apoptosis. 2008 Nov;13(11):1344-55. doi: 10.1007/s10495-008-0258-x.
12	Role of neutrophil elastase in stress-induced gastric mucosal injury in rats.J Lab Clin Med. 1998 Nov;132(5):432-9. doi: 10.1016/s0022-2143(98)90114-7.
13	Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents.BMC Gastroenterol. 2011 Aug 16;11:90. doi: 10.1186/1471-230X-11-90.
14	Protective mechanism of glutamine on the expression of proliferating cell nuclear antigen after cisplatin-induced intestinal mucosal injury.Pediatr Surg Int. 2011 Feb;27(2):151-8. doi: 10.1007/s00383-010-2798-8.
15	Assessment of the effect of laser irradiations at different wavelengths (660, 810, 980, and 1064 nm) on autophagy in a rat model of mucositis.Lasers Med Sci. 2015 May;30(4):1289-95. doi: 10.1007/s10103-015-1727-4. Epub 2015 Mar 3.
16	Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.J Clin Oncol. 2009 Sep 10;27(26):4333-8. doi: 10.1200/JCO.2008.21.2381. Epub 2009 Jul 27.
17	Irinotecan-induced mucositis is associated with changes in intestinal mucins.Cancer Chemother Pharmacol. 2009 Jun;64(1):123-32. doi: 10.1007/s00280-008-0855-y. Epub 2008 Nov 8.